Assess whether scientific advice should be sought before the next trial

SITUATION Phase-3 protocol with endpoint-sensitivity issues arrived with a CMO 483 that maps to the NDA CMC module for clinical-development physician. That is a Pharma & Life Sciences FDA Response and Labeling decision on scientific advice should be in a company with a CMC site change mid-review.

DECISION Clinical-development physician in a company with a CMC site change mid-review must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using phase-3 protocol with endpoint-sensitivity issues after a CMO 483 that maps to the NDA CMC module.

HYPOTHESES TO TEST 1. The population in phase-3 protocol with endpoint-sensitivity issues is the one a CMO 483 that maps to the NDA CMC module named, so Proceed under protocol follows for this FDA Response and Labeling file. 2. The population in phase-3 protocol with endpoint-sensitivity issues is adjacent only to a CMO 483 that maps to the NDA CMC module; Pause the pathway is the honest Pharma & Life Sciences call. 3. A company with a CMC site change mid-review already contained a CMO 483 that maps to the NDA CMC module before phase-3 protocol with endpoint-sensitivity issues arrived; no new FDA Response and Labeling path. 4. Provenance on phase-3 protocol with endpoint-sensitivity issues after a CMO 483 that maps to the NDA CMC module is broken; do not pick Proceed under protocol or Pause the pathway yet.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on scientific advice should be. 2. Check whether phase-3 protocol with endpoint-sensitivity issues supports the labeled claim clinical-development physician would keep. 3. Map FDA-response timing and owner in a company with a CMC site change mid-review. 4. For this Pharma & Life Sciences FDA Response and Labeling file, read phase-3 protocol with endpoint-sensitivity issues against a CMO 483 that maps to the NDA CMC module and write the one fact that would move scientific advice should be for clinical-development physician.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / FDA Response and Labeling packet (phase-3 protocol with endpoint-sensitivity issues after a CMO 483 that maps to the NDA CMC module). If phase-3 protocol with endpoint-sensitivity issues cannot force a Pharma & Life Sciences label under FDA Response and Labeling, stop. Do not invent missing evidence a company with a CMC site change mid-review does not have.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on scientific advice should be, then the evidence in phase-3 protocol with endpoint-sensitivity issues, then the action for clinical-development physician - Hypothesis scorecard against phase-3 protocol with endpoint-sensitivity issues: supported / rejected / untestable - What changes scientific advice should be if a CMO 483 that maps to the NDA CMC module is later withdrawn - Named option among Proceed under protocol, Pause the pathway, Escalate safety review and the fact that kills the others